Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Larry Parker

Orthopaedic Surgery of the Spine Huntsville, AL Medical Doctor

NPI 1770521551 CMS profile 670166

927 Franklin St, Huntsville, AL 35801

Open in the dashboard

General payments

$135,609

142 records reported · program years 2019–2025

Research payments

$3,000

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$209 paid to institutions, not to them · program year 2019

Through program year 2025, Larry Parker of Huntsville, AL is reported in the CMS Open Payments database as having received $135,609 across 142 general payments and $3,000 in research payments paid to them. Separately, studies naming them as principal investigator received $209 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,757 33
2024 General $47,968 36
2024 Research $3,000 10
2023 General $19,540 20
2022 General $1,180 4
2021 General $4,619 20
2020 General $6,942 14
2019 General $7,601 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Larry Parker
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Larry Parker were reported at $47,757. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Larry Parker Orthopaedic Surgery of the Spine median Middle half National median
2019 $7,601 $2,106 $337–$18,608 $163
2020 $6,942 $1,213 $156–$15,082 $114
2021 $4,619 $1,834 $271–$15,617 $132
2022 $1,180 $2,015 $320–$17,036 $149
2023 $19,540 $1,925 $336–$14,599 $160
2024 $47,968 $2,110 $341–$12,483 $164
2025 $47,757 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Precision Spine, Inc. $104,220 34 payments
  2. ulrich medical USA, Inc. $22,356 3 payments
  3. Medtronic, Inc. $3,149 8 payments
  4. Intrinsic Therapeutics $1,635 21 payments
  5. Highridge Medical LLC $1,500 1 payment
  6. Curiteva, Inc. $934 1 payment
  7. Horizon Therapeutics plc $333 24 payments
  8. Providence Medical Technology, Inc. $285 10 payments
  9. SI-BONE, Inc. $189 6 payments
  10. Spineology Inc. $152 1 payment
  11. Other $858 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $86,172 25 payments
  2. Consulting Fee $42,686 15 payments
  3. Food and Beverage $4,131 100 payments
  4. Travel and Lodging $2,619 2 payments
Products named General payments · program years 2019–2025
  1. ACCUFIT LATERAL PLATE SYSTEM $68,759 17 payments
  2. SURELOK MIS 3L $49,178 12 payments
  3. ShurFit MALIF Interbody System $48,414 10 payments
  4. REFORM TI CT MODULAR MIS PEDICLE SCREW SYSTEM $36,797 6 payments
  5. SHURFIT MALIF SYSTEM $19,205 5 payments
  6. MALIF Orthopedics $11,575 8 payments
  7. MD-VUE LATERAL ACCESS SYSTEM $8,115 3 payments
  8. MALIF Orthopedics $4,363 4 payments
  9. LATERAL PLATE SYSTEM $4,363 4 payments
  10. Vault C $2,500 1 payment
  11. Other $8,793 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Intrinsic Therapeutics $3,000 10 payments

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

2,646

Median for Orthopedic Surgery: 203

Drug cost

$20,973

Median for Orthopedic Surgery: $1,433

Branded share of claims

27.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Duloxetine Hcl Generic 267 $3,616
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 416 $3,376
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 287 $3,332
Gabapentin Generic 366 $2,413
Methylprednisolone Generic 261 $2,011
Cyclobenzaprine Hcl Generic 456 $1,632
Tizanidine Hcl Generic 100 $1,219
Methocarbamol Generic 127 $925
Diclofenac Sodium Generic 16 $551
Mupirocin Generic 41 $374

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$374,499

Of which drugs: $95

Medicare patients

350

Average age 73

Services billed

1,581

167 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Ischemic heart disease 39%
Depression 29%
Chronic kidney disease 24%
Osteoporosis 20%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 126 $90

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record